The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts

Breast Cancer Research and Treatment

Volumn 156, Issue 1, 2016, Pages 9-20

  Aleskandarany, Mohammed A ^a,b   Agarwal, Devika ^c   Negm, Ola H ^d   Ball, Graham ^c   Elmouna, Ahmed ^e   Ashankyty, Ibraheem ^e   Nuglozeh, Edem ^e   Fazaludeen, Mohammad F ^e   Diez Rodriguez, Maria ^a   Nolan, Christopher C ^a   Tighe, Patrick J ^d   Green, Andrew R ^a   Ellis, Ian O ^a   Rakha, Emad A ^a,b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b MENOUFIA UNIVERSITY   (Egypt)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITY OF HAIL   (Saudi Arabia)

Author keywords

Breast cancer; METABRIC; Reverse phase protein array; RPPA; STAT3

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; KI 67 ANTIGEN; MESSENGER RNA; METHOTREXATE; PHOSPHOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; STAT3 PROTEIN; TAMOXIFEN; STAT3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CELL NUCLEUS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAT3 GENE; TUMOR VOLUME; BREAST TUMOR; GENETIC DATABASE; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL NUCLEUS; COHORT STUDIES; CYTOPLASM; DATABASES, GENETIC; FEMALE; HUMANS; PHOSPHORYLATION; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS;

EID: 84961180341     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3709-z     Document Type: Article

References (35)

1. Levy DE, Darnell JE Jr (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3(9):651–662
2. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B (2009) Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 1171:59–76
3. Watson CJ, Neoh K (2008) The Stat family of transcription factors have diverse roles in mammary gland development. Semin Cell Dev Biol 19(4):401–406
4. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE (2005) New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell cycle (Georgetown, Tex), 4(9):1131–1133
5. Johnston PA, Grandis JR (2011) STAT3 signaling: anticancer strategies and challenges. Mol Interv 11(1):18–26
6. Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D et al (2010) Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res 16(8):2427–2434
7. Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q, Zhu J, Wei B, Tang Y (2013) STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. J Breast Cancer 16(1):40–49
8. Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, Rottenberg Y, Hamburger T, Mali B, Peretz T (2012) Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin Transl Oncol 14(3):232–236
9. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL (2003) Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9(2):594–600
10. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer J Int du Cancer 116(3):340–350
11. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310
12. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybittle JL et al (2007) Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999. Eur J Cancer (Oxford, England: 1990), 43(10):1548–1555
13. McCarty KS Jr, McCarty KS Sr (1984) Histochemical approaches to steroid receptor analyses. Semin Diagn Pathol 1(4):297–308
14. Aleskandarany MA, Negm OH, Rakha EA, Ahmed MA, Nolan CC, Ball GR, Caldas C, Green AR, Tighe PJ, Ellis IO (2012) TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. Breast Cancer Res Treat 136(2):419–427
15. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al (2012) The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486(7403):346–352
16. Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G, Campion L (2012) bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat 131(3):765–775
17. Santos CI, Costa-Pereira AP (1816) Signal transducers and activators of transcription-from cytokine signalling to cancer biology. Biochim Biophys Acta 1:38–49
18. Alvarez JV, Frank DA (2004) Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther 3(11):1045–1050
19. Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41(16):2502–2512
20. Clevenger CV (2004) Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165(5):1449–1460
21. Aleskandarany MA, Soria D, Green AR, Nolan C, Diez-Rodriguez M, Ellis IO, Rakha EA (2015) Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Breast Cancer Res Treat 151(2):325–333
22. Sonnenblick A, Uziely B, Nechushtan H, Kadouri L, Galun E, Axelrod JH, Katz D, Daum H, Hamburger T, Maly B et al (2013) Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 138(2):407–413
23. Mao Y, Qu Q, Zhang YZ, Liu JJ, Wang G, Liang Y, Shen KW (2014) The prognosis of signal transducer and activator of transcription 3 expression on breast cancer survival: a meta-analysis and retrospective study. Ann Oncol 25(suppl 1):i14
24. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, DePinho RA, Bonni A (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22(4):449–462
25. Gordziel C, Bratsch J, Moriggl R, Knosel T, Friedrich K (2013) Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer 109(1):138–146
26. Li MX, Bi XY, Huang Z, Zhao JJ, Han Y, Li ZY, Zhang YF, Li Y, Chen X, Hu XH et al (2015) Prognostic role of phospho-STAT3 in patients with cancers of the digestive system: a systematic review and meta-analysis. Plos One 10(5):e0127356
27. Sosonkina N, Starenki D, Park J-I (2014) The role of STAT3 in thyroid cancer. Cancers 6(1):526–544
28. Xiong H, Du W, Wang JL, Wang YC, Tang JT, Hong J, Fang JY (2012) Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berlin, Germany), 90(9):1037–1046
29. Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC et al (2013) Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 31(36):4520–4528
30. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T, Sekine I (2006) Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15(6):1445–1451
31. Seethala RR, Gooding WE, Handler PN, Collins B, Zhang Q, Siegfried JM, Grandis JR (2008) Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res 14(5):1303–1309
32. de la Iglesia N, Konopka G, Lim KL, Nutt CL, Bromberg JF, Frank DA, Mischel PS, Louis DN, Bonni A (2008) Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci 28(23):5870–5878
33. Li H, Xiao W, Ma J, Zhang Y, Li R, Ye J, Wang X, Zhong X, Wang S (2014) Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma. Int J Clin Exp Pathol 7(11):7989–7998
34. Kong H, Zhang Q, Zeng Y, Wang H, Wu M, Zheng T, Zeng Y, Shi H (2015) Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures. (1940–5901 (Electronic))
35. Ecker A, Simma O, Hoelbl A, Kenner L, Beug H, Moriggl R, Sexl V (2009) The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci 14:2944–2958